Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression
Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen
Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen
View: Text | PDF
Research Article Cell biology Clinical Research Oncology

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression

  • Text
  • PDF
Abstract

Loss-of-function mutations in genome maintenance genes fuel tumorigenesis through increased genomic instability. A subset of these tumor suppressors are challenging to identify due to context dependency, including functional interactions with other genes and pathways. Here, we searched for potential causal genes that impact tumor development and/or progression in breast cancer through functional-genetic screening of candidate genes. MYH4, encoding a class II myosin, emerged as a top hit impacting genomic stability. We show that MYH4 suppresses DNA replication stress by promoting replication licensing and replication fork progression. Moreover, we observed a strong synergistic relationship among class II myosins in suppressing replication-associated DNA damage. Genomic analysis of Pan-Cancer Analysis of Whole Genomes project breast cancer samples revealed frequent concomitant loss of TP53 with MYH4 and class II myosins on chromosome 17p. Notably, Myh4 disruption accelerated mouse mammary tumorigenesis in a Trp53-deficient background. In conclusion, our results suggest an unanticipated function of MYH4 in p53-mediated tumor suppression that can explain their combined loss in breast cancer.

Authors

Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen

×

Figure 5

MYH4 loss accelerates mammary tumorigenesis in a TP53-deficient background.

Options: View larger image (or click on image) Download as PowerPoint
MYH4 loss accelerates mammary tumorigenesis in a TP53-deficient backgrou...
(A) Deleted chromosomal segments that include both TP53 and MYH4 in the breast cancer (BRCA) subset of the PCAWG cohort (n = 211). TP53, MYH4, and other myosin class II family genes are highlighted in different colors. (B) Top panel: A pie chart depicting TP53 somatic mutation status of samples in the BRCA subset of the PCAWG cohort, color coded by TP53 status. Bottom panel: Combined assessment of TP53 and MYH4 status of samples in the BRCA subset of the PCAWG cohort, color coded by MYH4 status. (C) Schematic representation of intraductal injection of high-titer lentiviruses encoding Cre and nontargeting sgRNA (sgNT), or sgRNAs targeting Myh4 or Atm alleles in Rosa26-Cas9; Trp53fl/fl females. After harvesting, tumor material underwent histopathology and TIDE analysis. (D) Kaplan-Meier curves showing overall survival of Rosa26-Cas9; Trp53fl/fl mice when injected with sgNT (n = 7), sgAtm (n = 8), or sgMyh4 (n = 7). Mice injected with sgAtm and sgMyh4 show a significant difference when compared with sgNT (P = 0.009, log-rank test). Number of animals at risk over time is represented in the table at the bottom. One mouse in the Atm group is not represented because it was euthanized due a tumor at 197 days after injection. (E) Histopathological classification of the main tumor of each mouse injected with sgNT (n = 3), sgMyh4 (n = 7), or sgAtm (n = 8). The Atm group includes a subgroup, mixed carcinoma, where different carcinomas were found in the same lesion. In one specific case, a mix of adenocarcinoma and squamous cell carcinoma was observed.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts